Changes to the Code
S. 3228 · SIMSA Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 811 Authority and criteria for classification of substances
1 change the bill asks for here, 1 carried out
- Carried out:
Section 201 of the Controlled Substances Act (21 U.S.C. 811) is amended by adding at the end the following:
(k) Temporary and permanent scheduling of schedule A substances.— (1) In general.— The Attorney General may issue a temporary order adding a drug or substance to schedule A if the Attorney General finds that— (A) the drug or other substance satisfies the criteria for being …
§ 811(j)–(k)
Start of § 811 to (j)(2)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (j)(2)(B) | (B) | (B) | ||
| the date on which the Attorney General receives notification from the Secretary of Health and Human Services that the Secretary has approved an application under section 505(c), 512, or 571 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c), 360b, 360ccc] or section 262(a) of title 42, or indexed a drug under section 572 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 360ccc–1], with respect to the drug described in paragraph (1). | the date on which the Attorney General receives notification from the Secretary of Health and Human Services that the Secretary has approved an application under section 505(c), 512, or 571 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c), 360b, 360ccc] or section 262(a) of title 42, or indexed a drug under section 572 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 360ccc–1], with respect to the drug described in paragraph (1). | |||
| (j)(3) | (3) | (3) | ||
| A rule issued by the Attorney General under paragraph (1) shall become immediately effective as an interim final rule without requiring the Attorney General to demonstrate good cause therefor. The interim final rule shall give interested persons the opportunity to comment and to request a hearing. After the conclusion of such proceedings, the Attorney General shall issue a final rule in accordance with the scheduling criteria of subsections (b), (c), and (d) of this section and section 812(b) of this title. | A rule issued by the Attorney General under paragraph (1) shall become immediately effective as an interim final rule without requiring the Attorney General to demonstrate good cause therefor. The interim final rule shall give interested persons the opportunity to comment and to request a hearing. After the conclusion of such proceedings, the Attorney General shall issue a final rule in accordance with the scheduling criteria of subsections (b), (c), and (d) of this section and section 812(b) of this title. | |||
| (k) | (k) [inserted: Temporary and permanent scheduling of schedule A substances.—] | |||
| (k)(1) | (1) [inserted: In general.—] | |||
| [inserted: The Attorney General may issue a temporary order adding a drug or substance to schedule A if the Attorney General finds that—] | ||||
| (k)(1)(A) | (A) [inserted: ] | |||
| [inserted: the drug or other substance satisfies the criteria for being considered a schedule A substance; and] | ||||
| (k)(1)(B) | (B) [inserted: ] | |||
| [inserted: adding such drug or substance to schedule A will assist in preventing abuse of the drug or other substance.] | ||||
| (k)(2) | (2) [inserted: Duration of temporary scheduling order.—] | |||
| [inserted: A temporary scheduling order issued under paragraph (1) shall—] | ||||
| (k)(2)(A) | (A) [inserted: ] | |||
| [inserted: not take effect until 30 days after the date of the publication by the Attorney General of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued; and] | ||||
| (k)(2)(B) | (B) [inserted: ] | |||
| [inserted: expire not later than 5 years after the date on which the order becomes effective, except that the Attorney General may, during the pendency of proceedings under paragraph (5), extend the temporary scheduling order for up to 180 days.] | ||||
| (k)(3) | (3) [inserted: Effect of issuance of permanent scheduling order.—] | |||
| [inserted: A temporary scheduling order issued under paragraph (1) shall be vacated upon the issuance of a permanent order issued under paragraph (5) with regard to the same substance, or upon the subsequent issuance of any scheduling order under this section.] | ||||
| (k)(4) | (4) [inserted: Limitation on judicial review.—] | |||
| [inserted: A temporary scheduling order issued under paragraph (1) shall not be subject to judicial review.] | ||||
| (k)(5) | (5) [inserted: Permanent scheduling order.—] | |||
| (k)(5)(A) | (A) [inserted: In general.—] | |||
| [inserted: Except as provided in subparagraph (B), not earlier than 3 years after the date on which the Attorney General issues an order temporarily scheduling a drug or substance under this subsection, the Attorney General may, by rule, issue a permanent order adding the drug or other substance to schedule A if such drug or substance satisfies the criteria for being considered a schedule A substance.] | ||||
| (k)(5)(B) | (B) [inserted: Limitation.—] | |||
| [inserted: If the Secretary of Health and Human Services, in consultation with the Attorney General, has determined, based on relevant scientific studies and necessary data gathered by the Secretary of Health and Human Services and gathered by the Attorney General, that a drug or other substance that has been temporarily placed in schedule A does not have sufficient potential for abuse to warrant control in any schedule, and provides a 30-day written notice of such determination to the Attorney General, the Attorney General—] | ||||
| (k)(5)(B)(i) | (i) [inserted: ] | |||
| [inserted: may not issue a permanent scheduling order under subparagraph (A); and] | ||||
| (k)(5)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: not later than 30 days after the date on which the Attorney General receives such notice, shall issue an order immediately terminating the temporary scheduling order for the drug or other substance.] | ||||
| (k)(6) | (6) [inserted: Notice to HHS.—] | |||
| [inserted: Before initiating proceedings under paragraph (1), the Attorney General shall transmit notice of a temporary order proposed to be issued to the Secretary of Health and Human Services. In issuing an order under paragraph (1), the Attorney General shall take into consideration any comments submitted by the Secretary of Health and Human Services in response to a notice transmitted pursuant to this paragraph.] | ||||
21 U.S.C. § 812 Schedules of controlled substances
4 changes the bill asks for here, 3 carried out
- Carried out:
in subsection (a), by striking
five schedules of controlled substances, to be known as schedules I, II, III, IV, and V
and insertingsix schedules of controlled substances, to be known as schedules I, II, III, IV, V, and A
; - Carried out:
in subsection (b), by adding at the end the following:
(6) Schedule A.— (A) In general.— The drug or substance— (i) is or has been imported, or is offered for import, into the United States; (ii) has— (I) a chemical structure that is substantially similar to the chemical structure of a controlled substance in schedule I, II, III, …
- Not carried out:
in the matter preceding schedule I, by striking IV, and V and inserting IV, V, and A; and
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: schedule i, by striking QTEXT and inserting QTEXT; and - Carried out:
by adding at the end the following:
Schedule A Any substance temporarily or permanently scheduled by the Attorney General in accordance with section 201(k)..
§ 812(a)–(b)
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| § 812. Schedules of controlled substances | § 812. Schedules of controlled substances | |||
| (a) | (a) Establishment | (a) Establishment | ||
| There are established | There are established [inserted: six] schedules of controlled substances, to be known as schedules I, II, III, IV, [inserted: V, ]and [inserted: A]. Such schedules shall initially consist of the substances listed in this section. The schedules established by this section shall be updated and republished on a semiannual basis during the two-year period beginning one year after October 27, 1970, and shall be updated and republished on an annual basis thereafter. | |||
| (b) | (b) Placement on schedules; findings required | (b) Placement on schedules; findings required | ||
| Except where control is required by United States obligations under an international treaty, convention, or protocol, in effect on October 27, 1970, and except in the case of an immediate precursor, a drug or other substance may not be placed in any schedule unless the findings required for such schedule are made with respect to such drug or other substance. The findings required for each of the schedules are as follows: | Except where control is required by United States obligations under an international treaty, convention, or protocol, in effect on October 27, 1970, and except in the case of an immediate precursor, a drug or other substance may not be placed in any schedule unless the findings required for such schedule are made with respect to such drug or other substance. The findings required for each of the schedules are as follows: | |||
| (b)(1) | (1) Schedule I.— | (1) Schedule I.— |
§ 812(b)–(c)
(b)(1)(A)–(5)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(5)(B) | (B) | (B) | ||
| The drug or other substance has a currently accepted medical use in treatment in the United States. | The drug or other substance has a currently accepted medical use in treatment in the United States. | |||
| (b)(5)(C) | (C) | (C) | ||
| Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV. | Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV. | |||
| (b)(6) | (6) [inserted: Schedule A.—] | |||
| (b)(6)(A) | (A) [inserted: In general.—] | |||
| [inserted: The drug or substance—] | ||||
| (b)(6)(A)(i) | (i) [inserted: ] | |||
| [inserted: is or has been imported, or is offered for import, into the United States;] | ||||
| (b)(6)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: has—] | ||||
| (b)(6)(A)(ii)(I) | (I) [inserted: ] | |||
| [inserted: a chemical structure that is substantially similar to the chemical structure of a controlled substance in schedule I, II, III, IV, or V; and] | ||||
| (b)(6)(A)(ii)(II) | (II) [inserted: ] | |||
| [inserted: an actual or predicted stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I, II, III, IV, or V; and] | ||||
| (b)(6)(A)(iii) | (iii) [inserted: ] | |||
| [inserted: is not listed or otherwise included in any other schedule in this section or by regulation of the Attorney General.] | ||||
| (b)(6)(B) | (B) [inserted: Predicted stimulant, depressant, or hallucinogenic effect.—] | |||
| [inserted: For purpose of this paragraph, a predicted stimulant, depressant, or hallucinogenic effect on the central nervous system may be based on—] | ||||
| (b)(6)(B)(i) | (i) [inserted: ] | |||
| (b)(6)(B)(i)(I) | (I) [inserted: ] | |||
| [inserted: the chemical structure; and] | ||||
| (b)(6)(B)(i)(II) | (II) [inserted: ] | |||
| (b)(6)(B)(i)(II)(aa) | (aa) [inserted: ] | |||
| [inserted: the structure activity relationships; or] | ||||
| (b)(6)(B)(i)(II)(bb) | (bb) [inserted: ] | |||
| [inserted: binding receptor assays and other relevant scientific information about the substance;] | ||||
| (b)(6)(B)(ii) | (ii) [inserted: ] | |||
| (b)(6)(B)(ii)(I) | (I) [inserted: ] | |||
| [inserted: the current or relative potential for abuse of the substance; and] | ||||
| (b)(6)(B)(ii)(II) | (II) [inserted: ] | |||
| [inserted: the clandestine importation, manufacture, or distribution, or diversion from legitimate channels, of the substance; or] | ||||
| (b)(6)(B)(iii) | (iii) [inserted: ] | |||
| [inserted: the capacity of the substance to cause a state of dependence, including physical or psychological dependence that is similar to or greater than that of a controlled substance in schedule I, II, III, IV, or V.] | ||||
| (c) | (c) Initial schedules of controlled substances | (c) Initial schedules of controlled substances | ||
| Schedules I, II, III, IV, and V shall, unless and until amended pursuant to section 811 of this title, consist of the following drugs or other substances,1 by whatever official name, common or usual name, chemical name, or brand name designated: | Schedules I, II, III, IV, and V shall, unless and until amended pursuant to section 811 of this title, consist of the following drugs or other substances,1 by whatever official name, common or usual name, chemical name, or brand name designated: | |||
| Schedule I | Schedule I | |||
§ 812(e)–(19)
(a)–(e) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (e)(4) | (4) | (4) | ||
| Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit. | Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit. | |||
| (e)(5) | (5) | (5) | ||
| Not more than 100 milligrams of opium per 100 milliliters or per 100 grams. | Not more than 100 milligrams of opium per 100 milliliters or per 100 grams. | |||
| (19) | [inserted: Schedule A] | |||
| [inserted: Any substance temporarily or permanently scheduled by the Attorney General in accordance with section 201(k).] | ||||
| Schedule IV | Schedule IV | |||
21 U.S.C. § 822 Persons required to register
2 changes the bill asks for here, 2 carried out
- Carried out:
Section 302(e) of the Controlled Substances Act (21 U.S.C. 822(e)) is amended by adding at the end the following:
(3) (A) If a person is conducting research on a substance at the time the substance is added to schedule A, and such person, subject to an exemption that is in effect for investigational use, for that person, under section 505 of the Federal Food, Drug, and Cosmetic Act (21 …
The section already has a provision under this letter or number, so it would have two.
- Carried out:
Section 302(e) of the Controlled Substances Act (21 U.S.C. 822(e)), as amended by subsection (b) of this section, is amended by adding at the end the following:
(B) If a person is conducting research on a substance at the time the substance is added to schedule A, and such person is already registered to conduct research with a controlled substance in schedule I or II, then— (i) the person shall, within 30 days of the scheduling of the …
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 822(e)–(f)
Start of § 822 to (e)(4)(C)(ii) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (e)(4)(C)(iii) | (iii) | (iii) | ||
| the maintenance of records for the research sites; and | the maintenance of records for the research sites; and | |||
| (e)(4)(C)(iv) | (iv) | (iv) | ||
| any other matters necessary to ensure effective controls against diversion at the research sites. | any other matters necessary to ensure effective controls against diversion at the research sites. | |||
| (e)(3) | (3) [inserted: ] | |||
| (e)(3)(A) | (A) [inserted: ] | |||
| [inserted: If a person is conducting research on a substance at the time the substance is added to schedule A, and such person, subject to an exemption that is in effect for investigational use, for that person, under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) to the extent conduct with respect to such substance is pursuant to such exemption.] | ||||
| (e)(B) | (B) [inserted: ] | |||
| [inserted: If a person is conducting research on a substance at the time the substance is added to schedule A, and such person is already registered to conduct research with a controlled substance in schedule I or II, then—] | ||||
| (e)(B)(i) | (i) [inserted: ] | |||
| [inserted: the person shall, within 30 days of the scheduling of the newly-scheduled substance, submit a completed application for registration or modification of existing registration, to conduct research on such substance, in accordance with the regulations issued by the Attorney General;] | ||||
| (e)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: the person may continue to conduct the research on such substance until the application described in clause (i) is withdrawn by the applicant or until the Attorney General serves on the applicant an order to show cause proposing the denial of the application pursuant to section 304(c); and] | ||||
| (e)(B)(iii) | (iii) [inserted: ] | |||
| [inserted: if the Attorney General serves order to show cause under clause (ii) and the applicant requests a hearing, such hearing shall be held on an expedited basis and not later than 45 days after the request is made, except that the hearing may be held at a later time if so requested by the applicant.] | ||||
| (e)(C) | (C) [inserted: ] | |||
| [inserted: A person who is registered to conduct research with a controlled substance in schedule A may conduct research with another controlled substance in schedule I, only if—] | ||||
| (e)(C)(i) | (i) [inserted: ] | |||
| [inserted: the person has applied for a modification of the person's registration to authorize research with such other controlled substance in accordance with the regulations issued by the Attorney General;] | ||||
| (e)(C)(ii) | (ii) [inserted: ] | |||
| [inserted: the Attorney General has obtained verification from the Secretary that the research protocol submitted with the application is meritorious; and] | ||||
| (e)(C)(iii) | (iii) [inserted: ] | |||
| [inserted: the Attorney General has determined, not later than 30 days after receiving the application described in clause (i), that such activity is consistent with United States obligations under the Single Convention on Narcotic Drugs, 1961.] | ||||
| (e)(D) | (D) [inserted: ] | |||
| [inserted: Nothing in this paragraph shall be construed to alter the authority of the Attorney General to initiate proceedings to deny, suspend, or revoke any registration in accordance with sections 303 and 304.] | ||||
| (f) | (f) Inspection | (f) Inspection | ||
| (f)(1) | (1) | (1) | ||
| The Attorney General is authorized to inspect the establishment of a registrant or applicant for registration in accordance with the rules and regulations promulgated by him. | The Attorney General is authorized to inspect the establishment of a registrant or applicant for registration in accordance with the rules and regulations promulgated by him. | |||
Rest of § 822 unchanged
21 U.S.C. § 825 Labeling and packaging
1 change the bill asks for here, 1 carried out
- Carried out:
Section 305 of the Controlled Substances Act (21 U.S.C. 825) is amended by adding at the end the following:
(f) False labeling of schedule A controlled substances.— (1) It shall be unlawful to import or export, with intent to manufacture, distribute, or dispense, a schedule A substance or product containing a schedule A substance, unless the substance or product bears a label clearly …
§ 825(e)–(f)
Start of § 825 to (e)(2)(B)(ii) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (e)(2)(B)(ii)(I) | (I) | (I) | ||
| it is intended solely for investigational use as described in section 505(i) of such Act; and | it is intended solely for investigational use as described in section 505(i) of such Act; and | |||
| (e)(2)(B)(ii)(II) | (II) | (II) | ||
| such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application. | such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application. | |||
| (f) | (f) [inserted: False labeling of schedule A controlled substances.—] | |||
| (f)(1) | (1) [inserted: ] | |||
| [inserted: It shall be unlawful to import or export, with intent to manufacture, distribute, or dispense, a schedule A substance or product containing a schedule A substance, unless the substance or product bears a label clearly identifying a schedule A substance or product containing a schedule A substance by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).] | ||||
| (f)(2) | (2) [inserted: ] | |||
| (f)(2)(A) | (A) [inserted: ] | |||
| [inserted: A product described in subparagraph (B) is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this subsection if such product is labeled in the manner required under the Federal Food, Drug, and Cosmetic Act.] | ||||
| (f)(2)(B) | (B) [inserted: ] | |||
| [inserted: A product is described in this subparagraph if the product—] | ||||
| (f)(2)(B)(i) | (i) [inserted: ] | |||
| [inserted: is the subject of an approved application as described in section 505(b) or (j) of the Federal Food, Drug, and Cosmetic Act; or] | ||||
| (f)(2)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: is exempt from the provisions of section 505 of such Act relating to new drugs because—] | ||||
| (f)(2)(B)(ii)(I) | (I) [inserted: ] | |||
| [inserted: it is intended solely for investigational use as described in section 505(i) of such Act; and] | ||||
| (f)(2)(B)(ii)(II) | (II) [inserted: ] | |||
| [inserted: such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application.] | ||||
21 U.S.C. § 842 Prohibited acts B
6 changes the bill asks for here, 6 carried out
- Carried out:
in paragraph (16), by striking
or
at the end; - Carried out:
by redesignating paragraph (17) as paragraph (18); and
- Carried out:
by inserting after paragraph (16) the following:
(17) to violate section 305(f); or; and
- Carried out:
in subparagraph (B)(i), by striking
(17)
and inserting(18)
; and - Carried out:
in subparagraph (C), by inserting
or (17)
afterparagraph (16)
each place it appears; and - Carried out:
in paragraph (2)(D), by striking
(17)
and inserting(18)
.
§ 842(a)–(b)
Start of § 842 to (a)(14) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (a)(15) | (15) | (15) | ||
| to distribute a scheduled listed chemical product to a regulated seller, or to a regulated person referred to in section 830(b)(3)(B) of this title, unless such regulated seller or regulated person is, at the time of such distribution, currently registered with the Drug Enforcement Administration, or on the list of persons referred to under section 830(e)(1)(B)(v) of this title; | to distribute a scheduled listed chemical product to a regulated seller, or to a regulated person referred to in section 830(b)(3)(B) of this title, unless such regulated seller or regulated person is, at the time of such distribution, currently registered with the Drug Enforcement Administration, or on the list of persons referred to under section 830(e)(1)(B)(v) of this title; | |||
| (a)(16) | (16) | (16) | ||
| to violate subsection (e) of section 825 of this title; | to violate subsection (e) of section 825 of this title; | |||
| (a)(17) | (17) [inserted: ] | |||
| [inserted: to violate section 305(f); or] | ||||
| (a)(18) | [inserted: (18)] | |||
| in the case of a registered manufacturer or distributor of opioids, to fail to review the most recent information, directly related to the customers of the manufacturer or distributor, made available by the Attorney General in accordance with section 827(f) of this title. | in the case of a registered manufacturer or distributor of opioids, to fail to review the most recent information, directly related to the customers of the manufacturer or distributor, made available by the Attorney General in accordance with section 827(f) of this title. | |||
| (a) | As used in paragraph (11), the term “laboratory supply” means a listed chemical or any chemical, substance, or item on a special surveillance list published by the Attorney General, which contains chemicals, products, materials, or equipment used in the manufacture of controlled substances and listed chemicals. For purposes of paragraph (11), there is a rebuttable presumption of reckless disregard at trial if the Attorney General notifies a firm in writing that a laboratory supply sold by the firm, or any other person or firm, has been used by a customer of the notified firm, or distributed further by that customer, for the unlawful production of controlled substances or listed chemicals a firm distributes and 2 weeks or more after the notification the notified firm distributes a laboratory supply to the customer. For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 830(e)(1)(B)(v) of this title, the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 830(e)(1)(B)(v) of this title. | As used in paragraph (11), the term “laboratory supply” means a listed chemical or any chemical, substance, or item on a special surveillance list published by the Attorney General, which contains chemicals, products, materials, or equipment used in the manufacture of controlled substances and listed chemicals. For purposes of paragraph (11), there is a rebuttable presumption of reckless disregard at trial if the Attorney General notifies a firm in writing that a laboratory supply sold by the firm, or any other person or firm, has been used by a customer of the notified firm, or distributed further by that customer, for the unlawful production of controlled substances or listed chemicals a firm distributes and 2 weeks or more after the notification the notified firm distributes a laboratory supply to the customer. For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 830(e)(1)(B)(v) of this title, the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 830(e)(1)(B)(v) of this title. | ||
| (b) | (b) Manufacture | (b) Manufacture | ||
| It shall be unlawful for any person who is a registrant to manufacture a controlled substance in schedule I or II, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical, which is— | It shall be unlawful for any person who is a registrant to manufacture a controlled substance in schedule I or II, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical, which is— | |||
§ 842(c)Penalties(1)–(2)
(b)(1)–(c)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (1)(A) | (A) | (A) | ||
| Except as provided in subparagraph (B), (C), or (D) of this paragraph and paragraph (2), any person who violates this section shall, with respect to any such violation, be subject to a civil penalty of not more than $25,000. The district courts of the United States (or, where there is no such court in the case of any territory or possession of the United States, then the court in such territory or possession having the jurisdiction of a district court of the United States in cases arising under the Constitution and laws of the United States) shall have jurisdiction in accordance with section 1355 of title 28 to enforce this paragraph. | Except as provided in subparagraph (B), (C), or (D) of this paragraph and paragraph (2), any person who violates this section shall, with respect to any such violation, be subject to a civil penalty of not more than $25,000. The district courts of the United States (or, where there is no such court in the case of any territory or possession of the United States, then the court in such territory or possession having the jurisdiction of a district court of the United States in cases arising under the Constitution and laws of the United States) shall have jurisdiction in accordance with section 1355 of title 28 to enforce this paragraph. | |||
| (1)(B) | (B) | (B) | ||
| (1)(B)(i) | (i) | (i) | ||
| Except as provided in clause (ii), in the case of a violation of paragraph (5), (10), or ( | Except as provided in clause (ii), in the case of a violation of paragraph (5), (10), or ([inserted: 18]) of subsection (a), the civil penalty shall not exceed $10,000. | |||
| (1)(B)(ii) | (ii) | (ii) | ||
| In the case of a violation described in clause (i) committed by a registered manufacturer or distributor of opioids and related to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 827(f) of this title, the penalty shall not exceed $100,000. | In the case of a violation described in clause (i) committed by a registered manufacturer or distributor of opioids and related to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 827(f) of this title, the penalty shall not exceed $100,000. | |||
| (1)(C) | (C) | (C) | ||
| In the case of a violation of paragraph (16) of subsection (a) of this section by an importer, exporter, manufacturer, or distributor (other than as provided in subparagraph (D)), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of paragraph (16) of subsection (a). | In the case of a violation of paragraph (16) [inserted: or (17) ]of subsection (a) of this section by an importer, exporter, manufacturer, or distributor (other than as provided in subparagraph (D)), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of paragraph (16) [inserted: or (17) ]of subsection (a). | |||
| (1)(D) | (D) | (D) | ||
| In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of paragraph (16) of subsection (a) of this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term “at the retail level” refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of such paragraph (16) of subsection (a) shall be considered a separate violation. | In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of paragraph (16) of subsection (a) of this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term “at the retail level” refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of such paragraph (16) of subsection (a) shall be considered a separate violation. | |||
| (2) | (2) | (2) |
§ 842(c)Penalties(2)–(4)
(c)(2)(A)–(B) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (2)(C) | (C) | (C) | ||
| In addition to the penalties set forth elsewhere in this subchapter or subchapter II, any business that violates paragraph (11) of subsection (a) shall, with respect to the first such violation, be subject to a civil penalty of not more than $250,000, but shall not be subject to criminal penalties under this section, and shall, for any succeeding violation, be subject to a civil fine of not more than $250,000 or double the last previously imposed penalty, whichever is greater. | In addition to the penalties set forth elsewhere in this subchapter or subchapter II, any business that violates paragraph (11) of subsection (a) shall, with respect to the first such violation, be subject to a civil penalty of not more than $250,000, but shall not be subject to criminal penalties under this section, and shall, for any succeeding violation, be subject to a civil fine of not more than $250,000 or double the last previously imposed penalty, whichever is greater. | |||
| (2)(D) | (D) | (D) | ||
| In the case of a violation described in subparagraph (A) that was a violation of paragraph (5), (10), or ( | In the case of a violation described in subparagraph (A) that was a violation of paragraph (5), (10), or ([inserted: 18]) of subsection (a) committed by a registered manufacturer or distributor of opioids that relates to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 827(f) of this title, the criminal fine under title 18 shall not exceed $500,000. | |||
| (3) | (3) | (3) | ||
| Except under the conditions specified in paragraph (2) of this subsection, a violation of this section does not constitute a crime, and a judgment for the United States and imposition of a civil penalty pursuant to paragraph (1) shall not give rise to any disability or legal disadvantage based on conviction for a criminal offense. | Except under the conditions specified in paragraph (2) of this subsection, a violation of this section does not constitute a crime, and a judgment for the United States and imposition of a civil penalty pursuant to paragraph (1) shall not give rise to any disability or legal disadvantage based on conviction for a criminal offense. | |||
| (4) | (4) | (4) |
Rest of § 842 unchanged
21 U.S.C. § 952 Importation of controlled substances
2 changes the bill asks for here, 2 carried out
- Carried out:
in the matter preceding paragraph (1), by inserting
or drug or substance in schedule A
afterschedule I or II
; and - Carried out:
in paragraph (2), by inserting
or drug or substances in schedule A
afterschedule I or II
;
§ 952(a)
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| § 952. Importation of controlled substances | § 952. Importation of controlled substances | |||
| (a) | (a) Controlled substances in schedule I or II and narcotic drugs in schedule III, IV, or V; exceptions | (a) Controlled substances in schedule I or II and narcotic drugs in schedule III, IV, or V; exceptions | ||
| It shall be unlawful to import into the customs territory of the United States from any place outside thereof (but within the United States), or to import into the United States from any place outside thereof, any controlled substance in schedule I or II of subchapter I, or any narcotic drug in schedule III, IV, or V of subchapter I, or ephedrine, pseudoephedrine, or phenylpropanolamine, except that— | It shall be unlawful to import into the customs territory of the United States from any place outside thereof (but within the United States), or to import into the United States from any place outside thereof, any controlled substance in schedule I or II [inserted: or drug or substance in schedule A ]of subchapter I, or any narcotic drug in schedule III, IV, or V of subchapter I, or ephedrine, pseudoephedrine, or phenylpropanolamine, except that— | |||
| (a)(1) | (1) | (1) | ||
| such amounts of crude opium, poppy straw, concentrate of poppy straw, and coca leaves, and of ephedrine, pseudoephedrine, and phenylpropanolamine, as the Attorney General finds to be necessary to provide for medical, scientific, or other legitimate purposes, and | such amounts of crude opium, poppy straw, concentrate of poppy straw, and coca leaves, and of ephedrine, pseudoephedrine, and phenylpropanolamine, as the Attorney General finds to be necessary to provide for medical, scientific, or other legitimate purposes, and | |||
| (a)(2) | (2) | (2) | ||
| such amounts of any controlled substance in schedule I or II or any narcotic drug in schedule III, IV, or V that the Attorney General finds to be necessary to provide for the medical, scientific, or other legitimate needs of the United States— | such amounts of any controlled substance in schedule I or II or [inserted: drug or substances in schedule A or ]any narcotic drug in schedule III, IV, or V that the Attorney General finds to be necessary to provide for the medical, scientific, or other legitimate needs of the United States— | |||
| (a)(2)(A) | (A) | (A) | ||
| during an emergency in which domestic supplies of such substance or drug are found by the Attorney General to be inadequate, | during an emergency in which domestic supplies of such substance or drug are found by the Attorney General to be inadequate, | |||
| (a)(2)(B) | (B) | (B) | ||
| in any case in which the Attorney General finds that competition among domestic manufacturers of the controlled substance is inadequate and will not be rendered adequate by the registration of additional manufacturers under section 823 of this title, or | in any case in which the Attorney General finds that competition among domestic manufacturers of the controlled substance is inadequate and will not be rendered adequate by the registration of additional manufacturers under section 823 of this title, or |
Rest of § 952 unchanged
21 U.S.C. § 953 Exportation of controlled substances
2 changes the bill asks for here, 2 carried out
- Carried out:
in subsection (c), in the matter preceding paragraph (1), by inserting
or drug or substance in schedule A
afterschedule I or II
; and - Carried out:
in subsection (d), by inserting
or drug or substance in schedule A
afterschedule I or II
;
§ 953(b)–(e)
Start of § 953 to (a)(5) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b) | (b) Exception for exportation for special scientific purposes | (b) Exception for exportation for special scientific purposes | ||
| Notwithstanding subsection (a), the Attorney General may authorize any narcotic drug (including crude opium and coca leaves) in schedule I, II, III, or IV to be exported from the United States to a country which is a party to any of the international instruments mentioned in subsection (a) if the particular drug is to be applied to a special scientific purpose in the country of destination and the authorities of such country will permit the importation of the particular drug for such purpose. | Notwithstanding subsection (a), the Attorney General may authorize any narcotic drug (including crude opium and coca leaves) in schedule I, II, III, or IV to be exported from the United States to a country which is a party to any of the international instruments mentioned in subsection (a) if the particular drug is to be applied to a special scientific purpose in the country of destination and the authorities of such country will permit the importation of the particular drug for such purpose. | |||
| (c) | (c) Nonnarcotic controlled substances in schedule I or II | (c) Nonnarcotic controlled substances in schedule I or II | ||
| It shall be unlawful to export from the United States any nonnarcotic controlled substance in schedule I or II unless— | It shall be unlawful to export from the United States any nonnarcotic controlled substance in schedule I or II [inserted: or drug or substance in schedule A ]unless— | |||
| (c)(1) | (1) | (1) | ||
| it is exported to a country which has instituted and maintains a system which the Attorney General deems adequate for the control of imports of such substances; | it is exported to a country which has instituted and maintains a system which the Attorney General deems adequate for the control of imports of such substances; | |||
| (c)(2) | (2) | (2) | ||
| the controlled substance is consigned to a holder of such permits or licenses as may be required under the laws of the country of import; | the controlled substance is consigned to a holder of such permits or licenses as may be required under the laws of the country of import; | |||
| (c)(3) | (3) | (3) | ||
| substantial evidence is furnished to the Attorney General that (A) the controlled substance is to be applied exclusively to medical, scientific, or other legitimate uses within the country to which exported, (B) it will not be exported from such country, and (C) there is an actual need for the controlled substance for medical, scientific, or other legitimate uses within the country; and | substantial evidence is furnished to the Attorney General that (A) the controlled substance is to be applied exclusively to medical, scientific, or other legitimate uses within the country to which exported, (B) it will not be exported from such country, and (C) there is an actual need for the controlled substance for medical, scientific, or other legitimate uses within the country; and | |||
| (c)(4) | (4) | (4) | ||
| a permit to export the controlled substance in each instance has been issued by the Attorney General. | a permit to export the controlled substance in each instance has been issued by the Attorney General. | |||
| (d) | (d) Exception for exportation for special scientific purposes | (d) Exception for exportation for special scientific purposes | ||
| Notwithstanding subsection (c), the Attorney General may authorize any nonnarcotic controlled substance in schedule I or II to be exported from the United States if the particular substance is to be applied to a special scientific purpose in the country of destination and the authorities of such country will permit the importation of the particular drug for such purpose. | Notwithstanding subsection (c), the Attorney General may authorize any nonnarcotic controlled substance in schedule I or II [inserted: or drug or substance in schedule A ]to be exported from the United States if the particular substance is to be applied to a special scientific purpose in the country of destination and the authorities of such country will permit the importation of the particular drug for such purpose. | |||
| (e) | (e) Nonnarcotic controlled substances in schedule III or IV; controlled substances in schedule V | (e) Nonnarcotic controlled substances in schedule III or IV; controlled substances in schedule V | ||
| It shall be unlawful to export from the United States to any other country any nonnarcotic controlled substance in schedule III or IV or any controlled substances in schedule V unless— | It shall be unlawful to export from the United States to any other country any nonnarcotic controlled substance in schedule III or IV or any controlled substances in schedule V unless— | |||
| (e)(1) | (1) | (1) | ||
| there is furnished (before export) to the Attorney General documentary proof that importation is not contrary to the laws or regulations of the country of destination for consumption for medical, scientific, or other legitimate purposes; | there is furnished (before export) to the Attorney General documentary proof that importation is not contrary to the laws or regulations of the country of destination for consumption for medical, scientific, or other legitimate purposes; |
Rest of § 953 unchanged
21 U.S.C. § 954 Transshipment and in-transit shipment of controlled substances
1 change the bill asks for here, 1 carried out
- Carried out:
in section 1004(1) (21 U.S.C. 954(1)), in the matter preceding subparagraph (A), by inserting
or drug or substance in schedule A
afterschedule I
;
§ 954(1)–(2)
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| § 954. Transshipment and in-transit shipment of controlled substances | § 954. Transshipment and in-transit shipment of controlled substances | |||
| Notwithstanding sections 952, 953, and 957 of this title— | Notwithstanding sections 952, 953, and 957 of this title— | |||
| (1) | (1) | (1) | ||
| A controlled substance in schedule I may— | A controlled substance in schedule I [inserted: or drug or substance in schedule A ]may— | |||
| (1)(A) | (A) | (A) | ||
| be imported into the United States for transshipment to another country, or | be imported into the United States for transshipment to another country, or | |||
| (1)(B) | (B) | (B) | ||
| be transferred or transshipped from one vessel, vehicle, or aircraft to another vessel, vehicle, or aircraft within the United States for immediate exportation, | be transferred or transshipped from one vessel, vehicle, or aircraft to another vessel, vehicle, or aircraft within the United States for immediate exportation, | |||
| (1) | if and only if it is so imported, transferred, or transshipped (i) for scientific, medical, or other legitimate purposes in the country of destination, and (ii) with the prior written approval of the Attorney General (which shall be granted or denied within 21 days of the request). | if and only if it is so imported, transferred, or transshipped (i) for scientific, medical, or other legitimate purposes in the country of destination, and (ii) with the prior written approval of the Attorney General (which shall be granted or denied within 21 days of the request). | ||
| (2) | (2) | (2) | ||
| A controlled substance in schedule II, III, or IV may be so imported, transferred, or transshipped if and only if advance notice is given to the Attorney General in accordance with regulations of the Attorney General. | A controlled substance in schedule II, III, or IV may be so imported, transferred, or transshipped if and only if advance notice is given to the Attorney General in accordance with regulations of the Attorney General. |
21 U.S.C. § 955 Possession on board vessels, etc., arriving in or departing from United States
1 change the bill asks for here, 1 carried out
- Carried out:
in section 1005 (21 U.S.C. 955), by inserting
or drug or substance in schedule A
afterschedule I or II
; and
§ 955
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| § 955. Possession on board vessels, etc., arriving in or departing from United States | § 955. Possession on board vessels, etc., arriving in or departing from United States | |||
| It shall be unlawful for any person to bring or possess on board any vessel or aircraft, or on board any vehicle of a carrier, arriving in or departing from the United States or the customs territory of the United States, a controlled substance in schedule I or II or a narcotic drug in schedule III or IV, unless such substance or drug is a part of the cargo entered in the manifest or part of the official supplies of the vessel, aircraft, or vehicle. | It shall be unlawful for any person to bring or possess on board any vessel or aircraft, or on board any vehicle of a carrier, arriving in or departing from the United States or the customs territory of the United States, a controlled substance in schedule I or II or [inserted: drug or substance in schedule A or ]a narcotic drug in schedule III or IV, unless such substance or drug is a part of the cargo entered in the manifest or part of the official supplies of the vessel, aircraft, or vehicle. |
21 U.S.C. § 958 Registration requirements
1 change the bill asks for here, 1 carried out
- Carried out:
Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958) is amended by adding at the end the following:
(j) (1) The Attorney General shall register an applicant to import or export a schedule A substance if— (A) the applicant demonstrates that the schedule A substance will be used for research, analytical, or industrial purposes approved by the Attorney General; and (B) the …
§ 958(h)–(j)
Start of § 958 to (g) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (h) | (h) Separate registrations for each principal place of business | (h) Separate registrations for each principal place of business | ||
| A separate registration shall be required at each principal place of business where the applicant imports or exports controlled substances or list I chemicals. | A separate registration shall be required at each principal place of business where the applicant imports or exports controlled substances or list I chemicals. | |||
| (i) | (i) Emergency situations | (i) Emergency situations | ||
| Except in emergency situations as described in section 952(a)(2)(A) of this title, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under section 952(a) of this title authorizing the importation of such a substance, the Attorney General shall give manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. | Except in emergency situations as described in section 952(a)(2)(A) of this title, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under section 952(a) of this title authorizing the importation of such a substance, the Attorney General shall give manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. | |||
| (j) | (j) [inserted: ] | |||
| (j)(1) | (1) [inserted: ] | |||
| [inserted: The Attorney General shall register an applicant to import or export a schedule A substance if—] | ||||
| (j)(1)(A) | (A) [inserted: ] | |||
| [inserted: the applicant demonstrates that the schedule A substance will be used for research, analytical, or industrial purposes approved by the Attorney General; and] | ||||
| (j)(1)(B) | (B) [inserted: ] | |||
| [inserted: the Attorney General determines that such registration is consistent with the public interest and with the United States obligations under international treaties, conventions, or protocols in effect on the date of enactment of this subsection.] | ||||
| (j)(2) | (2) [inserted: ] | |||
| [inserted: In determining the public interest under paragraph (1)(B), the Attorney General shall consider—] | ||||
| (j)(2)(A) | (A) [inserted: ] | |||
| [inserted: maintenance of effective controls against diversion of particular controlled substances and any controlled substance in schedule A compounded therefrom into other than legitimate medical, scientific, research, or industrial channels, by limiting the importation and bulk manufacture of such controlled substances to a number of establishments which can produce an adequate and uninterrupted supply of these substances under adequately competitive conditions for legitimate medical, scientific, research, and industrial purposes;] | ||||
| (j)(2)(B) | (B) [inserted: ] | |||
| [inserted: compliance with applicable State and local law;] | ||||
| (j)(2)(C) | (C) [inserted: ] | |||
| [inserted: promotion of technical advances in the art of manufacturing substances described in subparagraph (A) and the development of new substances;] | ||||
| (j)(2)(D) | (D) [inserted: ] | |||
| [inserted: prior conviction record of applicant under Federal and State laws relating to the importation, manufacture, distribution, or dispensing of substances described in subparagraph (A);] | ||||
| (j)(2)(E) | (E) [inserted: ] | |||
| [inserted: past experience in the importation and manufacture of controlled substances, and the existence in the establishment of effective control against diversion; and] | ||||
| (j)(2)(F) | (F) [inserted: ] | |||
| [inserted: such other factors as may be relevant to and consistent with the public health and safety.] | ||||
| (j)(3) | (3) [inserted: ] | |||
| [inserted: If an applicant is registered to import or export a controlled substance in schedule I or II under subsection (a), the applicant shall not be required to apply for a separate registration under this subsection.] | ||||